Study M482
Study name | Moaddel R 2018 |
Title | Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects |
Overall design | In order to identify pathways that are responsible for ketamine's effect, a targeted metabolomic approach was carried out using a double-blind, placebo-controlled crossover design, with infusion order randomized with medication-free patients with treatment-resistant major depressive disorder (29 subjects) and healthy controls (25 subjects). Subjects received intravenous infusions of either saline solution or 0.5 mg/kg of ketamine hydrochloride, 2 weeks apart. The metabolomic profile of these subjects was characterized at multiple time points, and a comprehensive analysis was investigated between the following: MDD and healthy controls, treatment and placebo in both groups and the corresponding response to ketamine treatment. |
Study Type | Type1; Type2; Type3; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Treatment-resistant depression; Treatment-resistant depression; Healthy individuals; Healthy individuals; Healthy individuals; |
Criteria for depression | DSM-IV diagnosed MDD, MADRS >= 20 |
Sample size | 54 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: Nexera XR HPLC (Shimadzu) with QTRAP 6500+ (SCIEX); MS-based; LC-MS: API5500 LC-MS/MS System (AB SCIEX, USA); |
PMID | |
DOI | |
Citation | Moaddel R, Shardell M, Khadeer M, et al. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacology. 2018;235(10):3017-30. |
Metabolite |
